A promising molecule against chemotherapy-induced neuropathies
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Dec-2025 05:11 ET (30-Dec-2025 10:11 GMT/UTC)
Currently incurable, peripheral neuropathies are common neurological complications of chemotherapy, causing persistent pain, tingling and burning sensations in the feet and hands, sometimes even after treatment has ended. In the hope of offering a therapeutic option to affected patients, a research team led by a CNRS researcher has identified a molecule capable of preventing the onset of such side effects.
DTU researchers are behind a potentially groundbreaking antivenom that could revolutionize the treatment of venomous snakebites in Africa.
During cell division, chromosomal abnormalities – defects in chromosome number or structure – can occur, which can cause particularly aggressive forms of cancer. A new study has shed light on how chromosomal abnormalities arise in normal cells, the rates at which they do so, and how these rates are affected by various factors. To do this, the scientists developed a novel and versatile artificial intelligence (AI) tool called MAGIC, which combines automated microscopy and image analysis with single-cell genome sequencing. Understanding the molecular origins of cancer in this way could pave the way for better genetic detection tools and potential medical prevention strategies in the future.
Scientists reengineered chemo drug into spherical nucleic acids (SNAs), a globular form of DNA. Team tested the repackaged therapy on an animal model of acute myeloid leukemia, a fast-moving blood cancer. SNAs easily entered cancer cells and killed them from the inside while sparing healthy cells.
elderly. This study aims to assess the prevalence, mortality, and disability-adjusted life years (DALY) burden of cancer among individuals aged 60–94 worldwide from 1990 to 2021. Data on the prevalence, mortality, and DALY for 35 cancer types in the elderly were derived from the Global Burden of Disease Study (GBD) spanning 1990 to 2021. The analysis was performed at four stratified levels: global, 21 GBD regions, 204 countries, and five sociodemographic index (SDI) categories. Age-standardized rates for prevalence, mortality, and DALYs were computed. In 2021, the global elderly population (60–94 years) reported 691.13 × 105 [627.13 × 105, 773.82 × 105] cancer cases and 71.86 × 105 [65.07 × 105, 77.31 × 105] cancer deaths, with a DALY total of approximately 1394.17 × 105 [1281.20 × 105, 1495.54 × 105]. Trends indicate a gradual increase in cancer cases and mortality over time, with DALY rates escalating with aging. Notably, high-income North America exhibited the highest age-standardized prevalence. High SDI regions faced the most substantial elderly cancer burden. The burden of cancer among the elderly exhibits considerable variability globally, with developed socioeconomic areas experiencing a greater prevalence than those in underdeveloped regions, necessitating urgent attention from health professionals.